Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Casey Elliott

Physician Assistant Keller, TX Physician Assistant

NPI 1598951733 CMS profile 10578099

100 Bourland Rd Ste 170, Keller, TX 76248

Open in the dashboard

General payments

$11,275

618 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Casey Elliott of Keller, TX is reported in the CMS Open Payments database as having received $11,275 across 618 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,965 107
2024 General $2,121 112
2023 General $2,790 143
2022 General $2,047 118
2021 General $2,352 138

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Casey Elliott
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Casey Elliott were reported at $1,965. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Casey Elliott Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,352 $132 $37–$438 $132
2022 $2,047 $155 $48–$522 $149
2023 $2,790 $167 $52–$557 $160
2024 $2,121 $178 $55–$600 $164
2025 $1,965 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Pfizer Inc. $1,170 68 payments
  2. AbbVie, Inc. $1,104 76 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $795 50 payments
  4. Novo Nordisk Inc $755 54 payments
  5. GlaxoSmithKline, LLC. $578 24 payments
  6. AstraZeneca Pharmaceuticals LP $570 17 payments
  7. Lilly USA, LLC $446 28 payments
  8. Tris Pharma Inc $374 21 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $355 15 payments
  10. Janssen Pharmaceuticals, Inc $344 15 payments
  11. Other $4,783 250 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,136 611 payments
  2. Education $139 7 payments
Products named General payments · program years 2021–2025
  1. NURTEC ODT Pain $733 41 payments
  2. JARDIANCE $547 32 payments
  3. NURTEC ODT Primary Care $532 21 payments
  4. XYOSTED $496 26 payments
  5. UBRELVY $477 36 payments
  6. Ozempic $462 30 payments
  7. QULIPTA $444 33 payments
  8. RYBELSUS $408 29 payments
  9. Dyanavel XR $374 21 payments
  10. TRELEGY ELLIPTA $373 13 payments
  11. Other $8,948 486 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

1,984

Median for Physician Assistant: 241

Drug cost

$250,230

Median for Physician Assistant: $4,110

Branded share of claims

23.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 64 $65,711
Trulicity Dulaglutide Brand 45 $63,227
Eliquis Apixaban Brand 36 $31,583
Mounjaro Tirzepatide Brand 26 $29,057
Ozempic Semaglutide Brand 22 $27,568
Xigduo Xr Dapaglifloz Propaned/Metformin Brand 18 $13,850
Rosuvastatin Calcium Generic 177 $2,408
Atorvastatin Calcium Generic 193 $1,396
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 18 $1,215
Levothyroxine Sodium Generic 65 $835

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$32,795

Of which drugs: $4,712

Medicare patients

152

Average age 72

Services billed

709

50 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 41%
Diabetes 28%
Ischemic heart disease 28%
Chronic kidney disease 25%
Depression 20%
Atrial fibrillation 13%
Cancer 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 13 13 $3,760
Vaccine for influenza for injection into muscle 90662 Office 12 12 $900

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 37 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
$225 — —
JARDIANCE
$186 64 —
AIRSUPRA
$174 — —
JORNAY PM
$159 — —
VRAYLAR
$159 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 37 with Patron

Records

618 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record